Active, Not Recruiting
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer - CA209-77T
Opdateret:
26 juni, 2024
|
ClinicalTrials.gov
Fase
Køn
Aldersinterval
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants with suspected or histologically confirmed Stage IIA to IIIB non-small cell lung carcinoma (NSCLC) with disease that is considered resectable - No brain metastasis - Treatment-naive (no prior systemic anti-cancer treatment) - Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 - Ability to provide surgical or biopsy tumor tissue for biomarkers Exclusion Criteria: - Participants with an active, known or suspected autoimmune disease are excluded - Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection - Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy Other protocol defined inclusion/exclusion criteria could apply
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001